{"entity":{"id":"nct05503797","kind":"trial","name":"A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations","aka":[],"tldr":"A phase 2 trial of Plixorafenib in advanced solid tumours, run by Fore Biotherapeutics, now recruiting.","summary":"A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations is a phase 2 interventional study registered as NCT05503797 by Fore Biotherapeutics, with 254 participants planned, started 2023-02-21 and due to reach its primary completion in 2027-12-31. Interventions recorded: Plixorafenib.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05503797","url":"https://clinicaltrials.gov/study/NCT05503797"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05503797","phase":"2","setting":"A Phase 2 Master Protocol to Assess the Efficacy and Safety of FORE8394, an Inhibitor of BRAF Class 1 and Class 2 Alterations, in Participants With Cancer Harboring BRAF Alterations","sponsor":"Fore Biotherapeutics","enrolled":254,"outcomes":[]},"route":"/trials/nct05503797/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}]}}